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S U M M A R Y
Objectives: To describe elderly patients treated with prolonged suppressive antibiotic therapy for a
prosthetic joint infection (PJI) in cases where the infected prosthesis could not be removed.
Methods: All patients aged 80 years with a documented PJI and treated with prolonged suppressive
antibiotic therapy for more than 6 months were included retrospectively in this study. The following
events were noted: failure including persisting infection, relapse, new infection, treatment discontinua-
tion due to severe adverse events, and related death, and also unrelated death.
Results: Thirty-eight patients with a median age of 84 years (80–95 years) were included; there were
24 hip infections, 13 knee infections, and one shoulder infection. The main causative organisms were
Staphylococcus aureus (39%) and Streptococcus agalactiae (16%). The most commonly prescribed
antibiotics as prolonged suppressive therapy were penicillins. The median follow-up duration was
24 months; 60% of the patients were event-free at 24 months and were still on prolonged suppressive
antibiotic therapy. Fifteen events (six failures and nine unrelated deaths) were observed.
Hypoalbuminaemia, the presence of a sinus tract, and a staphylococcal PJI were associated with an
increased risk of an event.
Conclusions: Prolonged suppressive antibiotic therapy is an alternative therapy in elderly patients with
PJI when surgery is contraindicated and when the bacteria are susceptible to well-tolerated oral
antimicrobial therapy such as beta-lactams.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Infection is the most dramatic complication of arthroplasties,
which are used widely nowadays, especially in the elderly.1–3 In
France, approximately 100 000 total hip arthroplasties (THA) and
40 000 total knee arthroplasties (TKA) are implanted every year,
with an infection incidence of 1–2% for THA and 3% for TKA.4 In the
USA, over 500 000 primary arthroplasties are implanted every year
and over one million people currently live with a prosthetic joint.5
It is anticipated that by 2030 more than four million primary THA
and TKA replacements will be done per year.3 Sixty percent* Corresponding author. Tel.: +41 79 553 83 08; fax: +41 22 305 61 15.
E-mail address: virginie.prendki@hcuge.ch (V. Prendki).
http://dx.doi.org/10.1016/j.ijid.2014.09.012
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).of individuals with a THA in the USA are over 65 years of age and
5% over 85 years; further, 17% of patients with revision hip
replacements have at least three comorbidities.2
Treatment strategies to cure prosthetic joint infections (PJIs)
require removal, one- or two-stage replacement of the prosthesis,
and prolonged systemic antibiotic therapy for a total of
3 months.1,6 Patients with a well-ﬁxed prosthesis, without a sinus
tract, and who are within 30 days of prosthesis implantation or <3
weeks of onset of infectious symptoms should be proposed the
‘DAIR’ strategy of debridement, antibiotics, irrigation, and reten-
tion of the prosthesis.6 Other patients who do not meet these
criteria may also be proposed DAIR, or a minimal surgical strategy,
or no surgery at all, for example when a prosthesis exchange
strategy is unacceptable because of the risks involved and/or
patient refusal. In these cases, where relapse of infection is moreciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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deﬁned as an oral antibiotic therapy prescribed for a duration
longer than a curative treatment, may be used for palliative
purposes. Its aim is to inhibit bacterial growth around the
prosthesis and avoid the dissemination of infection.
Studies on this subject are few and of limited size.7–10 Most of
them included patients treated surgically and did not describe the
oldest and frailest patients. Moreover, they did not provide patient
demographics including age and treatment indications.
The objective of this study was to describe patients aged
80 years and older for whom surgical excision was contraindicated
as a result of medical and surgical conditions or patient refusal,
who received PSAT for a PJI for at least 6 months, and to describe
their treatment and outcome.
2. Methods
2.1. Study design and population
This retrospective observational study was carried out in a
French regional referral centre for osteoarticular infections at
the Groupe Hospitalier Diaconesses Croix Saint Simon in Paris.
All patients treated from January 2004 to December 2011 were
eligible. Cases were identiﬁed retrospectively using the registry
and medical charts of the orthopaedic department. Patients
were included if they were aged 80 years and had a
microbiologically conﬁrmed PJI, either by joint aspiration or
by intraoperative culture. Their prosthesis was not removed
and they were treated with suppressive antibiotic therapy for at
least 6 months.
The following data were collected: sex, age, medical history,
past history of PJI, ASA score (American Society of Anesthesiol-
ogists), symptoms of PJI (fever, pain, ﬁstula), type of PJI (acute or
chronic, postoperative or haematogenous), and the pathogen
isolated.
2.2. Prolonged suppressive antibiotic therapy
Indications for PSAT were collected and classiﬁed as very high
operative risk, very complex surgical intervention, or patient
refusal. The antibiotic therapy was detailed, including (1) the
initial intravenous antibiotic therapy and the following oral
regimen, which included the initial higher doses (considered as
curative treatment) and the subsequent lower doses, (2) the
duration of treatment, and (3) drug-related adverse events and
reasons for drug withdrawal. The duration of PSAT included the
initial intravenous treatment. Doses were prescribed according to
the national recommendations of France.11
2.3. Surgery
Patients underwent surgery only to drain an abscess, to reduce
the bacterial burden, or to perform a partial exchange in those with
severe pain and loosened components. The indications and types of
intervention were recorded.
2.4. Outcome
Patients were seen as outpatients every 3 to 6 months. For
patients not seen for more than 1 year, they or their referring
doctor was contacted by phone. The following events were
noted: treatment failure including persisting infection, relapse,
new infection, treatment discontinuation because of severe
adverse events, or related death. Unrelated death was included in
events.2.5. Deﬁnitions
PJI was deﬁned as a sinus tract communicating with the
prosthesis or clinical (local inﬂammatory signs including swelling,
warmth, erythema), laboratory (C-reactive protein (CRP) >5 mg/l),
or radiological signs (periosteal bone formation, subchondral
osteolysis) of infection, and positive cultures of joint ﬂuid
aspiration and a synovial leukocyte count >4.300  109/l with a
differential of >80% neutrophils in hip infection, or a synovial
leukocyte count >1.700  109/l with a differential of >65%
neutrophils in knee infection, or isolation of the same organism
from two or more cultures of intraoperative tissue specimens.
Acute infection was deﬁned as a duration of symptoms less than
1 month. Early infection was considered if it occurred within 1 year
after surgery (corresponding to time free of symptoms).
Persisting infection was deﬁned as persistence of clinical signs
of PJI. Reappearance of clinical signs of PJI after a symptom-free
period led to the diagnosis of ‘relapse’ if the same bacterial
organism was isolated as was found at inclusion, or as ‘new
infection’ if the organism was different.
2.6. Statistical analysis
Statistical analyses were performed with R (version 2.10.1)
software. A Kaplan–Meier curve was generated to assess overall
survival without an event. Factors related to the occurrence of an
event were analyzed with a univariate log-rank test, and the
unadjusted hazard ratio (HR) was performed with Cox analysis for
each factor. The level of signiﬁcance was set at p < 0.05.
3. Results
3.1. Patients
A total of 452 patients were treated for PJI during the study
period, 104 of whom were 80 years old. Of these, 38 patients were
included in the study, i.e., 8% of all patients and 36.5% of patients
aged 80 years. Their characteristics are detailed in Table 1. The
median duration of symptoms was 99 days (range 1–1825 days).
Fifteen patients had an acute infection and 15 an early-onset
infection. The infection was classiﬁedas postoperative in 23 patients.
Among these, the portal of entry was cutaneous in seven patients,
dental in three, urinary in three, digestive in three, and undeter-
mined in two. Two patients had endocarditis conﬁrmed by
echocardiography, including one with pacemaker-related endocar-
ditis. The other patient had concomitant cervical spondylodiscitis.
3.2. Microbiology
The microorganisms isolated in these patients are shown in
Table 2. Identiﬁcation was done by joint aspiration in 29 patients
(76%) and by intraoperative cultures in nine patients.
3.3. Prolonged suppressive antibiotic therapy
Indications for PSAT were a very high operative risk for
20 patients, a very complex surgical intervention for nine, and
patient refusal to have surgery for nine.
Thirty-two patients initially received an intravenous (IV)
antibiotic therapy for a median duration of 30 days (range 10–45
days) prior to the oral regimen. The IV agents used were beta-
lactams in 24 patients (amoxicillin in 10, cefazolin in 10,
ceftriaxone in two, and cloxacillin in two), clindamycin in four,
and vancomycin in four. They were associated with aminosides
for less than 1 week in 20 patients and with rifampin in
15 patients with susceptible Staphylococcus aureus infections.
Table 1
Baseline characteristics of 38 patients with prosthetic joint infections treated with
prolonged suppressive antibiotic therapy
Characteristics
Gender, male, n (%) 17 (45)
Age, years, median (range) 84 (80–95)
BMI, kg/m2, median (range) 26 (15.8–33.3)
Difﬁculty walking, n (%) 17 (45)
Bedsores, n (%) 3 (8)
Medical co-morbidity, n (%) 36 (95)
Cardiovascular disease,a n (%) 32 (84)
Chronic renal failure, n (%) 7 (18)
Long-term oral corticosteroids, n (%) 4 (11)
Malignancy within the last 5 years, n 3
Chronic dermatitis, n 3
Alzheimer’s disease, n 1
Insulin-requiring diabetes, n 1
Rheumatoid arthritis, n 1
Previous PJI, n (%) 14 (37)
ASA score of 3, n (%) 21 (55)








Physical examination, n (%)
Fever 14 (37)
Sinus tract 9 (24)
Laboratory examination
Total leukocyte count, 109/l, median (range) 8.820 (5.400–18.950)
CRP, mg/l, median (range) 74 (2–600)
Serum albumin, g/l, median (range) 29 (17–41)
BMI, body mass index; PJI, prosthetic joint infection; ASA, American Society of
Anesthesiologists; CRP, C-reactive protein.
a Cardiovascular disease: arterial hypertension (n = 15), cardiac arrhythmia
(n = 14; two patients with a pacemaker), coronary heart disease (n = 6; two patients
with a coronary bypass), valvular disease (n = 4), venous thromboembolic disease
(n = 5), ischaemic stroke (n = 4), peripheral arterial disease (n = 4).
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27 patients for a median duration of 45 days (range 15–60 days).
Eleven patients received a single-agent regimen and 16 a
combination of two effective oral antimicrobials. Drugs usedTable 2
Bacterial pathogens isolated in 38 prosthetic joint infections treated with prolonged
suppressive antibiotic therapy
Pathogen n (%) Event (failure)
Staphylococcus species 20 (53) 11 (6)
Staphylococcus aureus 15 (39) 10 (5)
Methicillin-sensitive 10 5 (3)
Methicillin-resistant 5 5 (2)
Coagulase-negative staphylococcia 5 1 (1)
Streptococcus species 7 (18) 1
Streptococcus agalactiae 6 (16) 1
Streptococcus salivarius 1 0
Enterococcus species 2 0
Enterococcus faecalis 2 0
Gram-negative bacilli 5 (13) 1
Enterobacteriaceaeb 2 0
Campylobacter fetus 3 1
Anaerobic bacteria 4 (11) 2 (1)
Propionibacterium acnes 3 1
Finegoldia magna 1 1 (1)
Bacteraemiac 9 (24) 4 (2)
Endocarditisd 2 (5) 1 (1)
a Staphylococcus epidermidis (n = 2), Staphylococcus lugdunensis (n = 2), unidenti-
ﬁed coagulase-negative Staphylococcus (n = 1).
b Citrobacter koseri (n = 1), Enterobacter cloacae (n = 1).
c Staphylococcus aureus (n = 4), Streptococcus agalactiae (n = 2), Enterococcus
faecalis (n = 2), Campylobacter fetus (n = 1).
d Streptococcus agalactiae (n = 1), Campylobacter fetus (n = 1).were amoxicillin (8), amoxicillin–clavulanate (1), cloxacillin (4),
clindamycin (7), co-trimoxazole (1), fusidic acid (5), minocycline
(1), levoﬂoxacin (1), peﬂacin (2), and rifampin (13). Curative
treatment was prescribed for a median duration of 59 days
(range 15–90 days).
The oral agents used at lower doses are detailed in Table 3; all
patients received a single-agent regimen.
3.4. Surgical interventions
Nine patients underwent surgery, including synovectomy
(n = 6), abscess drainage (n = 3), partial exchange (n = 1), and
excision of ﬁstula (n = 1). The pacemaker could not be removed in
the patient with pacemaker-related endocarditis.
3.5. Outcome
A total of 15 events were observed, with a median follow-up
duration of 24 months (range 6–98 months). Six failures occurred:
one persisting infection, three relapses, one related death, and one
treatment discontinuation. The patient who had a persisting
infection was infected with methicillin-resistant S. aureus (MRSA).
She had a sinus tract that persisted under antibiotic therapy,
but co-trimoxazole was continued because fever and local
inﬂammation decreased. She ﬁnally became bedridden and was
institutionalized. Relapses occurred in three patients with
methicillin-susceptible S. aureus (MSSA) treated with cloxacillin.
They were hospitalized and received new anti-staphylococcal
intravenous treatment and then another molecule for prolonged
suppression (cefazolin before each dialysis session for one patient,
clindamycin for the others). None of these patients underwent new
surgery and their outcome was favourable. The infection-related
death occurred in an 84-year-old patient whose prosthesis was
infected with Finegoldia magna. She was treated with clindamycin
but died from septic shock due to a new prosthetic infection. The
last patient with failure received prolonged co-trimoxazole for an
MRSA infection, which had to be stopped after 4 months of low oral
dose because of renal failure and recurrent Clostridium difﬁcile
colitis. Four more patients experienced reversible adverse events
(nausea and mycosis), but could continue their treatment.
Nine patients died of unrelated causes (two from cardiac failure,
one from renal failure, one from mesenteric ischemia, one from
intestinal obstruction, one from pulmonary embolism, and three
from bedsore complications). In a Kaplan–Meier analysis, 60%
of the patients were event-free at 24 months and still on PSAT
(Figure 1). Their treatment was considered successful. Six out of
seven patients with a streptococcal PJI belonged to this group
and were treated successfully with amoxicillin, the only event
occurring 8 years after the beginning of PSAT from death unrelated
to infection.
The results of univariate analysis are presented in Tables 4 and
5. Variables associated with an increased risk of an event were
age 85 years (P = 0.016), female gender (P = 0.023), difﬁculty
walking (P = 0.049), hypoalbuminaemia (P = 0.019), the presence
of a sinus tract (P = 0.020), and a staphylococcal PJI (P = 0.01).
4. Discussion
PSAT is sometimes proposed in patients for whom surgical
strategies are unacceptable or refused by the patient or their
family. This has already been used for infections of other devices,
such as in aortic prostheses for example.13 Of the studies
speciﬁcally addressing long-term suppression in PJIs, only two
documented the median age, which was 66 and 77 years,
respectively.9,10 The present study is the ﬁrst to address patients
over 80 years of age and is the largest series to date with a
Table 3
Agents used for chronic suppression in 38 patients with prosthetic joint infections (low-dose oral antibiotic therapy)
Agents used for oral PSAT Daily dosage Number of patients (%) Microorganism (number of patients treated)
Amoxicillin 1000 mg tid 14 (37) Streptococcus spp (7), Enterococcus faecalis (2), Campylobacter fetus (2),
Propionibacterium acnes (3)
Cloxacillin 1000 mg tid 10 (26) MS Staphylococcus aureus (6), MS coagulase-negative Staphylococcus (4)
Clindamycin 600 mg tid 8 (21) MS Staphylococcus aureus (3), MR Staphylococcus aureus (2),
MR coagulase-negative Staphylococcus (1), Finegoldia magna (1),
Campylobacter fetus (1)
TMP–SMX 800 mg–160 mg bid 3 MR Staphylococcus aureus (1), Enterobacter cloacae (1),
Citrobacter koseri (1)
Fusidic acida 500 mg tid 2 MS Staphylococcus aureus (1), MR Staphylococcus aureus (1)
Doxycycline 100 mg bid 1 MR Staphylococcus aureus (1)
PSAT, prolonged suppressive antibiotic therapy; tid, three times daily; bid, twice daily; MS, methicillin-susceptible; MR, methicillin-resistant; TMP–SMX, trimethoprim–
sulfamethoxazole.
a Fusidic acid is not recommended as single therapy.
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This strategy was used in a third of the patients aged 80 years in
our centre. Joint arthroplasty has low morbidity and mortality, but
mostly in very elderly patients (80 years) in our experience.12 At
the beginning of the study, a limited surgical procedure was
systematically performed to reduce the bacterial burden. However,
over time this was performed less often and only in cases with a
voluminous abscess, large sinus tract, or uncontrolled sepsis. Thus
our study differs from others: only a few patients had undergone
surgery, in contrast to previous studies in which all patients had
undergone surgical debridement.8–10 Indeed, we have described
the frailest of the oldest patients; their median age was 10 years
above that of the patients included in the study by Rao et al.10Most
of them had major co-morbidities, predominantly cardiovascular
diseases (84%), and half of them had an ASA score of 3. Moreover,
14 had already had one or more infections at the same surgical site,
which contributed to the decision not to operate further.
One of the strengths of our study is the documentation of the
bacteria using deep sampling, excluding patients for whom the
diagnosis was made by surface swab sampling or sinus tract
culture. Arthrocentesis and synovial ﬂuid analysis showed that
most of the bacteria were quite sensitive, allowing oral treatment.
The bacterial distribution in our series, with staphylococci and
streptococci the ﬁrst aetiologies of PJI, is explained mostly by aFigure 1. Clinical outcome of 38 patients with prosthetic joint infections treated
with prolonged suppressive antibiotic therapy. Kaplan–Meier curve showing
survival without event (95% conﬁdence interval in grey). Events are deﬁned as
failure and unrelated death.large haematogenous origin. The portal of entry was primarily
cutaneous, dental, and urinary tract, as also described in the
literature.14 In the present series, 53% of PJIs were due to
staphylococci (predominantly MSSA), which is in keeping with
other PJI data.1,15 However this rate is lower than those found in
previous studies on PSAT by Segreti et al. and Rao et al., who found
staphylococcal infections in up to 83% and 86%, respectively.9,10
Treatment failures were most often associated with staphylo-
cocci compared to other bacteria, as described previously in the
literature.9,10 Five of six failures were due to S. aureus PJI (83%), but
only 33% of total S. aureus PJI failed. Brandt et al. reported failure in
64% of PJI due to S. aureus; these were treated with debridement
and retention of the prosthesis.16 Segreti et al. and Rao et al., on the
other hand, demonstrated a good response for PJIs treated with
prosthesis retention, with a 69% success rate for S. aureus PJI after a
mean follow-up of 5 years, using mostly minocycline and rifampin,
molecules that achieve high intracellular levels. We did not use
these drugs as long-term therapy in our elderly patients because of
signiﬁcant side effects (digestive disorders, enzyme induction).
However, we did use doxycycline as a single-therapy once.
Other variables signiﬁcantly associated with the occurrence of
an event were female gender, which may in part be explained by
the longer life span of women, the presence of a sinus tract, which
has already been associated with treatment failure,17 and
hypoalbuminaemia, which has already been described as being
associated with postoperative medical complications in elderly
patients with hip fractures.18 Therefore, optimal nutrition should
be achieved in patients on PSAT. The age of the prosthesis and
duration of symptoms were not found to be associated with
treatment failure, which is in contrast to other studies.
The ideal PSAT regimen has not been established. We treated
the great majority of our patients with IV antibiotic therapy for
10 days to 6 weeks, according to the clinical presentation, the
bacterial susceptibility, and the treatment outcome. Their treat-
ment was continued with high-dose oral therapy for 4–6 weeks to
reduce the bacterial burden and then with a lower dose for
prolonged antimicrobial suppression. The doses used for oral
antibiotic therapy in PJIs are higher in France than in other
countries.11 We generally used amoxicillin 2 g three times daily
for initial oral doses and then 1 g three times daily for the long
duration chronic suppression. Osmon et al.6 recommend oral
amoxicillin 500 mg three times daily for chronic oral antimicrobial
suppression in streptococcal PJI.
Elderly patients are known to be more at risk of drug-related
toxicity,19 drug interactions, and adherence issues,20 but antimi-
crobial adverse events were limited in our experience, since only
one patient had to interrupt the treatment. In the absence of a
contraindication, beta-lactams were used in 63% of the patients
and they were well-tolerated, as reported in other studies.7–10
In guidelines from the USA, ﬁrst-generation cephalosporins
Table 4
Univariate assessment of risk factors for treatment failure among patients with prosthetic joint infections treated with prolonged suppressive antibiotic therapy: qualitative
variables
Variables Total number with characteristic Number of events (%) Unadjusted HR (95% CI) p-Valuea
Age, years
80–85 22 6 (27%)
85 16 9 (56%) 3.87 (1.29–11.62) 0.016
Gender
Male 17 5 (29%)
Female 21 10 (48%) 4.55 (1.23–16.74) 0.023
Joint
Hip 24 11(46%)
Knee 13 4 (31%) 0.7 (0.22–2.24) 0.549
Shoulder 1 0 -
Arthroplasty
Primary implant 24 12 (50%)
Revised implant 14 3 0.35 (0.10–1.25) 0.105
Gait disorder
Absent 17 3 (18%) 0.049
Yes 21 12 (57%) 3.62 (1.002–13.05)
ASA score
2 17 4 (24%)
3 21 11 (52%) 2.57 (0.80–8.26) 0.112
Time free of symptoms, months
<12 14 4 (29%)
>12 23 10 (43%) 1.20 (0.37–3.93) 0.760
Sinus tract
Absent 29 9 (31%) 0.020
Yes 9 6 (67%) 3.74 (1.24–11.35)
Microbiology
Other bacteria 18 4 (22%)
Staphylococcus 20 11 (55%) 7.30 (1.61–33.19) 0.010
Bacteraemia
Absent 29 10 (34%)
Yes 9 5 (56%) 1.24 (0.38–3.98) 0.722
Surgery
No 29 8 (28%)
Yes 9 7 (78%) 2.11 (0.71–6.26) 0.178
Duration of symptoms
<30 days 15 5 (33%)
30–90 days 5 2 (40%) 1.18 (0.22–6.53) 0.850
>90 days 18 8 (44%) 1.52 (0.45–5.08) 0.500
HR, hazard ratio; CI, conﬁdence interval; ASA, American Society of Anesthesiologists.
a Log-rank test.
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bial suppression,6 whereas dicloxacillin is recommended as an
alternative therapy. In our study, 13% of failures occurred with
beta-lactams. All streptococcal infections were treated effectively
with amoxicillin. Half of the failures occurred with cloxacillin, but
seven patients treated with this molecule had a good outcome with
a median duration of cloxacillin of 715 days. However, as
mentioned above, we used cloxacillin 1 g three times daily for
chronic suppression instead of 500 mg three times daily as per the
Infectious Diseases Society of America guidelines. Co-trimoxazole
was used three times with two failures and we do not recommend
this drug for PSAT. Fusidic acid, which was used twice because of
no other therapeutic option, should not be used as a single
antimicrobial therapy as this induces bacterial resistance.21 TheTable 5
Univariate assessment of risk factors for treatment failure among patients with prostheti
variables
















HR, hazard ratio; CI, conﬁdence interval; BMI, body mass index; CRP, C-reactive protei
a Log-rank test.suppressive approach is not without risk as the localized septic
process can extend and become a systemic infection, but this did
not occur in our patients.
One could criticize the use of prolonged antimicrobial agents in
the current ecological context, where antimicrobial resistance is a
global threat.22 Faced with the major public health issue of
increasing PJIs in aging people,23 consideration is needed to treat
each patient according to the principles of biomedical ethics.20,24
Our study is limited by its single-centre retrospective nature and
its small size. We did not include patients who received less than
6 months of PSAT. Consequently, we are likely to have under-
estimated PSAT failures, which is an important bias of our study.
Nevertheless, we can conclude that PSAT is beneﬁcial in















V. Prendki et al. / International Journal of Infectious Diseases 29 (2014) 184–189 189the microorganism is susceptible to oral antimicrobial therapy,
such as beta-lactams. Prolonged follow-up of the patient and
optimal nutrition are recommended, particularly for patients with
a staphylococcal infection, with a low serum albumin level, or with
a sinus tract.
Larger studies with functional, geriatric, and ecological assess-
ment would be of value to determine the design, the place, and the
consequences of PSAT and to better target the patients who would
beneﬁt from this treatment.
Conﬂict of interest: The authors declare no conﬂict of interest
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